Danish Construction Stock News

If you want to compound wealth in the stock market, you can do so by buying an index fund. But if you pick the right...

To the annoyance of some shareholders, Pandora A/S ( CPH:PNDORA ) shares are down a considerable 26% in the last month...

What Novo Nordisk’s recent performance data tells you Novo Nordisk (CPSE:NOVO B) has seen mixed share performance recently, with about a 3% decline over 1 day, a broadly flat past week, and gains over the past month and past 3 months. See our latest analysis for Novo Nordisk. At a share price of DKK 377.55, Novo Nordisk’s recent 21.79% 1 month share price return contrasts with a weaker 1 year total shareholder return of 29.56% and a stronger 5 year total shareholder return of 83.01%. This...

Some investors rely on dividends for growing their wealth, and if you're one of those dividend sleuths, you might be...

Amylyx Pharmaceuticals recently selected AMX0318, a long-acting GLP-1 receptor antagonist discovered in collaboration with Gubra, as a development candidate for post-bariatric hypoglycemia and other rare diseases, triggering a US$4,000,000 milestone payment and positioning Gubra for more than US$50,000,000 in potential future milestones plus mid-single digit royalties. The move underlines how Gubra’s partnered peptide programs can translate preclinical research into tangible milestone income...

Ambu A/S recently presented at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, highlighting its single-use endoscopy focus and turnaround progress. The company used the conference platform to showcase innovation, scalable operations, and an improved financial outlook that could influence how investors view its recovery narrative. Next, we examine how Ambu’s emphasis on single-use endoscopy leadership and turnaround progress at the conference shapes its investment...

Hove A/S ( CPH:HOVE ) shares have continued their recent momentum with a 27% gain in the last month alone. The annual...

Brd. Klee A/S ( CPH:KLEE B ) is about to trade ex-dividend in the next three days. The ex-dividend date generally...

Genmab A/S recently reported topline Phase 3 EPCORE DLBCL-1 data showing that subcutaneous epcoritamab monotherapy improved progression-free survival versus standard chemo‑immunotherapy in previously treated, transplant‑ineligible diffuse large B‑cell lymphoma patients, with safety consistent with its known profile. This is the first Phase 3 trial to show a progression-free survival benefit for a CD3xCD20 bispecific antibody used as monotherapy in relapsed or refractory diffuse large B‑cell...

It's shaping up to be a tough period for Bang & Olufsen A/S ( CPH:BO ), which a week ago released some disappointing...

Novo Nordisk A/S ( CPH:NOVO B ) shares have had a really impressive month, gaining 26% after a shaky period beforehand...

Why the Revolution Wind ruling matters for Ørsted A US federal judge has allowed Ørsted (CPSE:ORSTED) to restart construction on its nearly finished, roughly US$5.0b Revolution Wind project, removing the prior national security suspension and shifting attention back to project delivery and capital returns. See our latest analysis for Ørsted. Against this legal win, Ørsted’s share price has a 1 day return of 3.4% and a 90 day share price return of 13.15%. However, the 1 year total shareholder...

Bavarian Nordic A/S has begun a shareholder-authorized buyback program as of January 7, 2026, allowing repurchases of up to 10% of its share capital on Nasdaq Copenhagen at prices within 10% of the prevailing market price, with the mandate running through December 31, 2026. This move to retire shares adds a new capital allocation element that could influence how investors view Bavarian Nordic’s earnings profile and ownership structure. We’ll now examine how this newly launched share...

Q2 2026 results snapshot Bang & Olufsen (CPSE:BO) has just posted Q2 2026 revenue of DKK 676 million, with basic EPS of DKK 0.40 loss and net income loss of DKK 53 million setting the tone for the quarter. The company has seen quarterly revenue move between DKK 544 million and DKK 698 million over the last six reported periods, while basic EPS has ranged from a profit of DKK 0.06 to a loss of DKK 0.40. This gives investors a clear view of how top line stability contrasts with ongoing earnings...

If you are wondering whether Novo Nordisk shares are offering good value right now, looking at how the current price lines up with different valuation methods can give you a clearer picture. The stock last closed at DKK 378.25, with returns of 3.2% over 7 days, 19.5% over 30 days, 14.5% year to date, a 35.7% decline over 1 year, a 17.2% decline over 3 years, and 85.9% over 5 years. This sets a mixed backdrop for assessing where value might sit today. Recent news around Novo Nordisk has...

Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...

Vestas Wind Systems (CPSE:VWS) has attracted fresh attention after disclosing new turbine orders across Europe, North America, and Australia, covering more than 1,000 MW of capacity under long term service agreements. See our latest analysis for Vestas Wind Systems. These multi region turbine orders arrive after a strong run in the shares, with a 90 day share price return of 41.07% and a 1 year total shareholder return of 93.52%. However, the 3 and 5 year total shareholder returns of 14.36%...

Novo Nordisk has launched its FDA-approved oral Wegovy pill in the U.S., rapidly widening access through major pharmacies, Amazon Pharmacy, and telehealth platforms as the first GLP-1 pill for chronic weight management and cardiovascular risk reduction. This shift toward a once-daily pill, backed by phase 3 data and expanding distribution partnerships, could materially influence how patients choose between oral and injectable GLP-1 therapies in obesity care. We’ll now examine how the broad...

In recent months, GN Store Nord A/S has been working to rebuild its position in audio and hearing technology by tightening costs, integrating operations more effectively, and continuing to develop its Jabra and hearing-aid product lines. This quieter turnaround effort matters because it ties GN’s professional and medical audio strengths directly to persistent trends in remote work and age-driven hearing care demand. We’ll now examine how GN Store Nord’s renewed emphasis on cost savings and...

Danske Bank has continued its DKK 5.00 billion share buy-back programme, having repurchased 18,155,560 shares so far, while also appointing Dr Fiona Browne as its first Head of AI to lead a new AI centre of excellence in Belfast. Together, the ongoing buy-back and creation of a dedicated AI leadership role highlight Danske Bank’s twin focus on capital return discipline and building in-house technological capabilities. We’ll now examine how the expanding share buy-back and new AI centre of...

Those holding Shape Robotics A/S ( CPH:SHAPE ) shares would be relieved that the share price has rebounded 26% in the...

To the annoyance of some shareholders, cBrain A/S ( CPH:CBRAIN ) shares are down a considerable 26% in the last month...

SP Group A/S ( CPH:SPG ) shares have continued their recent momentum with a 26% gain in the last month alone. The last...

With a price-to-earnings (or "P/E") ratio of 41.9x DSV A/S ( CPH:DSV ) may be sending very bearish signals at the...